Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOCRYST PHARMACEUTICALS INCBCRX · Entity 315 | Director | June 11, 2026 | June 15, 2026 |
| ProQR Therapeutics N.V.PRQR · Entity 5946 | Director | March 18, 2026 | March 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOCRYST PHARMACEUTICALS INC
Report date June 11, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 80,646 |
Reported balance
After 2026-06-11 transaction · row 1
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 15,294 · Balance 80,646 F1: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. |
| Automatic Stock Option GrantSEC Table II · derivative / convertible security · Conversion / exercise price $8.50 · Expires 2036-06-11 | Direct | 33,540 |
Reported balance
After 2026-06-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-11 · Grant · Acquired 33,540 · Balance 33,540 F2: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. |
Filing footnotes · ownership attribution and instrument terms
F1: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.
F2: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.
ProQR Therapeutics N.V.
Report date March 18, 2026 · Filed March 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 43,623 |
Reported balance
Holding disclosure · report date 2026-03-18 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 43,623 |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.73 · Expires 2033-10-31 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: Fully vested. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.10 · Expires 2029-06-30 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F1: Fully vested. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.91 · Expires 2029-12-31 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F1: Fully vested. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.20 · Expires 2030-12-31 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance Not disclosed F1: Fully vested. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.02 · Expires 2032-02-29 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance Not disclosed F1: Fully vested. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.67 · Expires 2032-04-30 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance Not disclosed F1: Fully vested. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.74 · Expires 2033-05-17 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance Not disclosed F2: 25% of the shares subject to such option vest and become exercisable on May 18, 2024, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.98 · Expires 2033-12-31 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance Not disclosed F3: 25% of the shares subject to such option vest and become exercisable on January 1, 2025, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.65 · Expires 2034-12-31 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance Not disclosed F4: 25% of the shares subject to such option vest and become exercisable on January 1, 2026, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.02 · Expires 2035-12-31 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance Not disclosed F5: 25% of the shares subject to such option vest and become exercisable on January 1, 2027, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Fully vested.
F2: 25% of the shares subject to such option vest and become exercisable on May 18, 2024, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
F3: 25% of the shares subject to such option vest and become exercisable on January 1, 2025, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
F4: 25% of the shares subject to such option vest and become exercisable on January 1, 2026, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
F5: 25% of the shares subject to such option vest and become exercisable on January 1, 2027, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 15, 2026 20:06 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 33,540 | $0.00 Strike: $8.50 | $0.00 |
DisclosureSEC source: 0000882796-26-000035 · form4.xml · derivative · entry 2 HEGGIE THERESA · CIK 0001760020 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,540 Underlying: Common Stock · 33,540 shares Expires 2036-06-11 F2 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 20:06 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 15,294 | $0.00 | $0.00 |
DisclosureSEC source: 0000882796-26-000035 · form4.xml · nonDerivative · entry 1 HEGGIE THERESA · CIK 0001760020 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,646 F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. Read SEC document |
| March 20, 2026 Filed Mar 24, 2026 20:02 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionAutomatic Stock Option Grant · Derivative | 49,933 | $0.00 Strike: $6.30 | $0.00 |
DisclosureSEC source: 0000882796-26-000017 · form4.xml · derivative · entry 3 HEGGIE THERESA · CIK 0001760020 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 49,933 shares Expires 2034-06-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 20, 2026 Filed Mar 24, 2026 20:02 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 49,933 | $10.11 | $504,822.63 |
DisclosureSEC source: 0000882796-26-000017 · form4.xml · nonDerivative · entry 2 HEGGIE THERESA · CIK 0001760020 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,352 F1 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $10.09 to $10.14. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| March 20, 2026 Filed Mar 24, 2026 20:02 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 49,933 | $6.30 | $314,577.90 |
DisclosureSEC source: 0000882796-26-000017 · form4.xml · nonDerivative · entry 1 HEGGIE THERESA · CIK 0001760020 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,285 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 13, 2025 Filed Aug 15, 2025 12:24 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionAutomatic Stock Option Grant · Derivative | 40,000 | $0.00 Strike: $5.41 | $0.00 |
DisclosureSEC source: 0001127602-25-020491 · form4.xml · derivative · entry 5 HEGGIE THERESA · CIK 0001760020 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2030-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 13, 2025 Filed Aug 15, 2025 12:24 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionAutomatic Stock Option Grant · Derivative | 30,000 | $0.00 Strike: $2.91 | $0.00 |
DisclosureSEC source: 0001127602-25-020491 · form4.xml · derivative · entry 4 HEGGIE THERESA · CIK 0001760020 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2029-05-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 13, 2025 Filed Aug 15, 2025 12:24 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 70,000 | $8.51 | $595,868.00 |
DisclosureSEC source: 0001127602-25-020491 · form4.xml · nonDerivative · entry 3 HEGGIE THERESA · CIK 0001760020 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,352 F1 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $8.48 to $8.55. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| August 13, 2025 Filed Aug 15, 2025 12:24 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 40,000 | $5.41 | $216,400.00 |
DisclosureSEC source: 0001127602-25-020491 · form4.xml · nonDerivative · entry 2 HEGGIE THERESA · CIK 0001760020 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,352 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 13, 2025 Filed Aug 15, 2025 12:24 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 30,000 | $2.91 | $87,300.00 |
DisclosureSEC source: 0001127602-25-020491 · form4.xml · nonDerivative · entry 1 HEGGIE THERESA · CIK 0001760020 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,352 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 20:19 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 27,181 | $0.00 Strike: $10.40 | $0.00 |
DisclosureSEC source: 0001171843-25-003913 · ownership.xml · derivative · entry 2 HEGGIE THERESA · CIK 0001760020 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,181 Underlying: Common Stock · 27,181 shares Expires 2035-06-12 F2 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 20:19 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-25-003913 · ownership.xml · nonDerivative · entry 1 HEGGIE THERESA · CIK 0001760020 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,352 F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. Read SEC document |
| June 14, 2024 Filed Jun 14, 2024 20:25 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 6,698 | $6.11 | $40,924.78 |
DisclosureSEC source: 0001127602-24-018715 · form4.xml · nonDerivative · entry 2 HEGGIE THERESA · CIK 0001760020 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,852 F2 · shares: These shares were sold with the sole purpose of generating sufficient proceeds to cover the tax liability incurred in connection with the vesting of 16,745 Restricted Stock Units on June 13, 2024. F3 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $6.08 to $6.15. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:25 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 49,933 | $0.00 Strike: $6.30 | $0.00 |
DisclosureSEC source: 0001127602-24-018715 · form4.xml · derivative · entry 3 HEGGIE THERESA · CIK 0001760020 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,933 Underlying: Common Stock · 49,933 shares Expires 2034-06-12 F4 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:25 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 6,820 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-018715 · form4.xml · nonDerivative · entry 1 HEGGIE THERESA · CIK 0001760020 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,550 F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. Read SEC document |
| May 31, 2024 Filed Jun 3, 2024 20:33 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 870 | $6.46 | $5,620.20 |
DisclosureSEC source: 0001127602-24-017302 · form4.xml · nonDerivative · entry 1 HEGGIE THERESA · CIK 0001760020 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,730 F1 · shares: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $11,250. Read SEC document |
| February 29, 2024 Filed Mar 4, 2024 21:32 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 999 | $5.63 | $5,624.37 |
DisclosureSEC source: 0001127602-24-008140 · form4.xml · nonDerivative · entry 1 HEGGIE THERESA · CIK 0001760020 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,860 F1 · shares: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $11,250. Read SEC document |
| November 30, 2023 Filed Dec 1, 2023 21:40 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 956 | $5.88 | $5,621.28 |
DisclosureSEC source: 0001127602-23-028607 · form4.xml · nonDerivative · entry 1 HEGGIE THERESA · CIK 0001760020 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,861 F1 · shares: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $11,250. Read SEC document |
| August 31, 2023 Filed Sep 5, 2023 20:41 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 791 | $7.11 | $5,624.01 |
DisclosureSEC source: 0001127602-23-023693 · form4.xml · nonDerivative · entry 1 HEGGIE THERESA · CIK 0001760020 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,905 F1 · shares: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $11,250. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 20:29 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 39,072 | $0.00 Strike: $8.18 | $0.00 |
DisclosureSEC source: 0001127602-23-018767 · form4.xml · derivative · entry 2 HEGGIE THERESA · CIK 0001760020 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,072 Underlying: Common Stock · 39,072 shares Expires 2033-06-13 F2 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 20:29 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 16,745 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-018767 · form4.xml · nonDerivative · entry 1 HEGGIE THERESA · CIK 0001760020 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,114 F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 20:32 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 680 | $8.27 | $5,623.60 |
DisclosureSEC source: 0001127602-23-017552 · form4.xml · nonDerivative · entry 1 HEGGIE THERESA · CIK 0001760020 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,369 F1 · shares: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $11,250. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 21:38 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 635 | $8.85 | $5,619.75 |
DisclosureSEC source: 0001127602-23-008383 · form4.xml · nonDerivative · entry 1 HEGGIE THERESA · CIK 0001760020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,689 F1 · security: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $11,250. Read SEC document |
| November 30, 2022 Filed Dec 2, 2022 23:30 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 421 | $13.36 | $5,624.56 |
DisclosureSEC source: 0001127602-22-026830 · form4.xml · nonDerivative · entry 1 HEGGIE THERESA · CIK 0001760020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,054 F1 · security: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $11,250. Read SEC document |
| August 31, 2022 Filed Sep 2, 2022 20:29 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 404 | $13.90 | $5,615.60 |
DisclosureSEC source: 0001127602-22-022003 · form4.xml · nonDerivative · entry 1 HEGGIE THERESA · CIK 0001760020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,633 F1 · security: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $11,250. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 20:45 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 30,022 | $0.00 Strike: $10.79 | $0.00 |
DisclosureSEC source: 0001127602-22-017157 · form4.xml · derivative · entry 2 HEGGIE THERESA · CIK 0001760020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,022 Underlying: Common Stock · 30,022 shares Expires 2032-06-07 F2 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 20:45 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 12,866 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-017157 · form4.xml · nonDerivative · entry 1 HEGGIE THERESA · CIK 0001760020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,229 F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. Read SEC document |
| May 31, 2022 Filed Jun 2, 2022 20:40 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 1,138 | $9.31 | $10,594.78 |
DisclosureSEC source: 0001127602-22-016402 · form4.xml · nonDerivative · entry 1 HEGGIE THERESA · CIK 0001760020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,363 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $11,250, prorated to $10,597.83 based on the increase in the annual retainer fee effective April 18, 2022. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:38 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 602 | $16.61 | $9,999.22 |
DisclosureSEC source: 0001127602-22-007722 · form4.xml · nonDerivative · entry 1 HEGGIE THERESA · CIK 0001760020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,225 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 21:10 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 829 | $12.06 | $9,997.74 |
DisclosureSEC source: 0001127602-21-030052 · form4.xml · nonDerivative · entry 1 HEGGIE THERESA · CIK 0001760020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,623 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 20:30 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 628 | $15.92 | $9,997.76 |
DisclosureSEC source: 0001127602-21-024774 · form4.xml · nonDerivative · entry 1 HEGGIE THERESA · CIK 0001760020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,794 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000. Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 20:18 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 317 | $15.77 | $4,999.09 |
DisclosureSEC source: 0001127602-21-018474 · form4.xml · nonDerivative · entry 1 HEGGIE THERESA · CIK 0001760020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,166 F1 · security: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $10,000. Read SEC document |
| May 25, 2021 Filed May 27, 2021 20:21 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 40,000 | $0.00 Strike: $13.28 | $0.00 |
DisclosureSEC source: 0001127602-21-018177 · form4.xml · derivative · entry 1 HEGGIE THERESA · CIK 0001760020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-05-25 F1 · security: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 21:50 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 463 | $10.78 | $4,991.14 |
DisclosureSEC source: 0001127602-21-008754 · form4.xml · nonDerivative · entry 1 HEGGIE THERESA · CIK 0001760020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,849 F1 · security: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $10,000. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 21:21 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 978 | $5.11 | $4,997.58 |
DisclosureSEC source: 0001127602-20-030291 · form4.xml · nonDerivative · entry 1 HEGGIE THERESA · CIK 0001760020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,386 F1 · security: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $10,000. Read SEC document |
| August 31, 2020 Filed Sep 2, 2020 20:39 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 1,204 | $4.15 | $4,996.60 |
DisclosureSEC source: 0001127602-20-024644 · form4.xml · nonDerivative · entry 1 HEGGIE THERESA · CIK 0001760020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,408 F1 · security: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $10,000. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:22 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 1,112 | $4.50 | $4,998.44 |
DisclosureSEC source: 0001127602-20-018715 · form4.xml · nonDerivative · entry 1 HEGGIE THERESA · CIK 0001760020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,204 F1 · security: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $10,000. Read SEC document |
| May 12, 2020 Filed May 14, 2020 20:21 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 40,000 | $0.00 Strike: $5.41 | $0.00 |
DisclosureSEC source: 0001127602-20-016565 · form4.xml · derivative · entry 1 HEGGIE THERESA · CIK 0001760020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2030-05-12 F1 · security: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. Read SEC document |
| March 01, 2020 Filed Mar 3, 2020 21:56 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 1,666 | $3.00 | $4,998.00 |
DisclosureSEC source: 0001127602-20-009089 · form4.xml · nonDerivative · entry 1 HEGGIE THERESA · CIK 0001760020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,092 F1 · security: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $10,000. Read SEC document |
| December 01, 2019 Filed Dec 3, 2019 22:17 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 1,754 | $2.85 | $4,998.90 |
DisclosureSEC source: 0001127602-19-034170 · form4.xml · nonDerivative · entry 1 HEGGIE THERESA · CIK 0001760020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,426 F1 · security: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $10,000. Read SEC document |
| November 18, 2019 Filed Nov 18, 2019 21:08 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | PurchaseCommon Stock | 5,000 | $1.45 | $7,250.00 |
DisclosureSEC source: 0001127602-19-033017 · form4.xml · nonDerivative · entry 1 HEGGIE THERESA · CIK 0001760020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,672 Read SEC document |
| September 01, 2019 Filed Sep 4, 2019 20:16 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 1,672 | $2.99 | $4,999.28 |
DisclosureSEC source: 0001127602-19-027871 · form4.xml · nonDerivative · entry 1 HEGGIE THERESA · CIK 0001760020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,672 F1 · security: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $10,000. Read SEC document |
| May 29, 2019 Filed May 31, 2019 20:16 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 30,000 | $0.00 Strike: $2.91 | $0.00 |
DisclosureSEC source: 0001127602-19-020306 · form4.xml · derivative · entry 1 HEGGIE THERESA · CIK 0001760020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-05-29 F1 · security: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. Read SEC document |
| December 03, 2018 Filed Dec 6, 2018 21:27 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantNon-Qualified Stock Option · Derivative | 30,000 | $0.00 Strike: $9.27 | $0.00 |
DisclosureSEC source: 0001127602-18-035379 · form4.xml · derivative · entry 1 HEGGIE THERESA · CIK 0001760020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2028-12-03 F1 · shares: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Amended and Restated Stock Incentive Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.